Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

<p>&#8211; Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated &#8211; &#8211; Monotherapy arm has advanced to a fourth cohort, with initial monotherapy PK and safety data expected in the fourth quarter of 2023 and topline monotherapy data expected in 2024 &#8211; &#8211; New guidance for initial combination PK and [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/sensei-biotherapeutics-announces-initiation-of-combination-arm-for-phase-1-2-clinical-study-of-sns-101-with-regenerons-libtayo/">Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>